拓扑替康联合用药抗肿瘤研究进展  

Progress on researches for topotecan in combination drug therapy

作　　者：张哲[1] 孙立[1] 袁胜涛[1] 

机构地区：[1]中国药科大学新药筛选中心

出　　处：《中国临床药理学与治疗学》2015年第1期106-112,共7页Chinese Journal of Clinical Pharmacology and Therapeutics

摘　　要：恶性肿瘤是世界公认的对人类健康危害最为严重的疾病之一,受到学者的极大关注。拓扑替康(topotecan)属喜树碱类,为拓扑异构酶Ⅰ抑制剂,它能导致DNA复制叉断裂,该作用方式使其不易产生耐药性。拓扑替康主要用于卵巢癌和小细胞肺癌的临床治疗,疗效显著。拓扑替康与多种化合物,如顺铂、索拉菲尼、贝伐单抗、氨柔比星、培美曲塞、吉西他滨等联合使用,均具有一定的抗肿瘤增效作用,因此研究联合应用拓扑替康抗肿瘤的课题值得关注。Malignant neoplasm threats peo- ple＇s health seriously and draws wide attention of the scholars. Topotecan （TPT）, a topoison- erase inhibitor, can induce the fragmentation of DNA replication fork, therefore it is not easy to produce drug resistance. Also topotecan has been widely and efficiently used in the treatment of ovarian carcinoma and small cell lung carcino- ma. TPT has exhibited certain antitumor syner-gistic effect by combining with a variety of com- pounds, such as platinum, sorafini, bevacizum- ab, amrubicin, pemetrexed, gemcitabine. Therefore, it is worthy to investigate the appli- cations of topotecan in combination drug thera- py.

关 键 词：拓扑替康 肿瘤 联合应用 

分 类 号：R965[医药卫生—药理学]